Thomas L Schwartz

Summary

Affiliation: SUNY Upstate Medical University
Country: USA

Publications

  1. ncbi request reprint Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression
    Usman Hameed
    Department of Psychiatry, Upstate Medical University, 750 E Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:77-81. 2005
  2. pmc Glutamate neurocircuitry: theoretical underpinnings in schizophrenia
    Thomas L Schwartz
    Department of Psychiatry, State University of New York Upstate Medical University Syracuse, NY, USA
    Front Pharmacol 3:195. 2012
  3. pmc Psychopharmacological Practice: The DSM Versus The Brain
    Thomas L Schwartz
    Associate Professor, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA Tele 315 464 3100
    Mens Sana Monogr 11:25-41. 2013
  4. pmc Psychopharmacology Today: Where are We and Where Do We Go From Here?
    Thomas L Schwartz
    Associate Professor of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Mens Sana Monogr 8:6-16. 2010
  5. pmc Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
    Mandeep Singh
    SUNY Upstate Medical University, Psychiatry Department, Syracuse, NY, USA
    Neuropsychiatr Dis Treat 8:123-30. 2012
  6. doi request reprint Utilizing pharmacodynamic properties of second-generation antipsychotics to guide treatment
    T Schwartz
    SUNY Upstate Medical University, Psychiatry Department, Syracuse, New York 13210, USA
    Drugs Today (Barc) 48:283-92. 2012
  7. ncbi request reprint Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia
    Thomas L Schwartz
    SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    Curr Pharm Des 18:1580-92. 2012
  8. doi request reprint Treatment strategies for dosing the second generation antipsychotics
    Thomas L Schwartz
    Department of Psychiatry State, University of New York Upstate Medical University, NY, USA
    CNS Neurosci Ther 17:110-7. 2011
  9. doi request reprint Acamprosate calcium as augmentation therapy for anxiety disorders
    Thomas L Schwartz
    Psychiatry Department, State University of New York SUNY Upstate Medical University, Syracuse, NY, USA
    Ann Pharmacother 44:1930-2. 2010
  10. ncbi request reprint An open-label study of tiagabine as augmentation therapy for anxiety
    Thomas L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:167-72. 2005

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression
    Usman Hameed
    Department of Psychiatry, Upstate Medical University, 750 E Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:77-81. 2005
    ..Our objective was to determine if there is a difference in antidepressant effectiveness between disorders in the newer antidepressants (SSRIs) in a primary care setting when a formal systematic depression treatment protocol is used...
  2. pmc Glutamate neurocircuitry: theoretical underpinnings in schizophrenia
    Thomas L Schwartz
    Department of Psychiatry, State University of New York Upstate Medical University Syracuse, NY, USA
    Front Pharmacol 3:195. 2012
    ..In conclusion, there is a brief review of potential schizophrenia treatments that rely on the etiologic theory provided in the body of the paper...
  3. pmc Psychopharmacological Practice: The DSM Versus The Brain
    Thomas L Schwartz
    Associate Professor, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA Tele 315 464 3100
    Mens Sana Monogr 11:25-41. 2013
    ..The concept that the DSM may be excellent for clinical diagnostic purposes, but less correct in its assumptions for a psychopharmacologist's treatment approaches will be discussed...
  4. pmc Psychopharmacology Today: Where are We and Where Do We Go From Here?
    Thomas L Schwartz
    Associate Professor of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Mens Sana Monogr 8:6-16. 2010
    ..Finally, I will comment on the psychotropic pipeline, which may be added to our armamentarium in the future...
  5. pmc Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
    Mandeep Singh
    SUNY Upstate Medical University, Psychiatry Department, Syracuse, NY, USA
    Neuropsychiatr Dis Treat 8:123-30. 2012
    ..This combined activity results in serotonin facilitation across the brain's serotonergic pathways, which has been termed by the authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI...
  6. doi request reprint Utilizing pharmacodynamic properties of second-generation antipsychotics to guide treatment
    T Schwartz
    SUNY Upstate Medical University, Psychiatry Department, Syracuse, New York 13210, USA
    Drugs Today (Barc) 48:283-92. 2012
    ..All SGAs share common properties; however, each individual SGA has a unique pharmacodynamic profile that may be utilized to guide and individualize treatment...
  7. ncbi request reprint Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia
    Thomas L Schwartz
    SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    Curr Pharm Des 18:1580-92. 2012
    ..This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms...
  8. doi request reprint Treatment strategies for dosing the second generation antipsychotics
    Thomas L Schwartz
    Department of Psychiatry State, University of New York Upstate Medical University, NY, USA
    CNS Neurosci Ther 17:110-7. 2011
    ..Aims: To review relevant data regarding the second generation antipsychotics and their empirical dosing strategies. To further review and comment theoretically in these areas where substantial, definitive data are lacking...
  9. doi request reprint Acamprosate calcium as augmentation therapy for anxiety disorders
    Thomas L Schwartz
    Psychiatry Department, State University of New York SUNY Upstate Medical University, Syracuse, NY, USA
    Ann Pharmacother 44:1930-2. 2010
    ..This GABA-glutamate imbalance is thought to play a role in the development of anxiety. Acamprosate calcium is thought to restore this chemical imbalance in alcohol withdrawal...
  10. ncbi request reprint An open-label study of tiagabine as augmentation therapy for anxiety
    Thomas L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:167-72. 2005
    ..Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the CNS, and agents that modulate GABA neurotransmission have shown promise in the treatment of anxiety disorders and are often used as augmentation agents...
  11. ncbi request reprint An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 19:25-30. 2007
    ....
  12. doi request reprint Obesity and psychotropics
    Nikhil Nihalani
    SUNY Upstate Medical University, NY, USA
    CNS Neurosci Ther 18:57-63. 2012
    ..This article serves to provide a succinct review regarding the epidemiology, etiology, and treatment options for psychotropic-induced obesity...
  13. ncbi request reprint Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions
    James L Megna
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA
    Ann Clin Psychiatry 23:131-40. 2011
    ..However, these effects have been more widespread among adults with serious and persistent mental illness...
  14. ncbi request reprint Tiagabine in anxiety disorders
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA
    Expert Opin Pharmacother 7:1977-87. 2006
    ..Tiagabine may be a useful addition to currently available drugs for anxiety; however, the data from small open-label investigations remain to be confirmed in larger controlled studies...
  15. ncbi request reprint Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Psychosomatics 43:451-5. 2002
    ..Both groups had similar improvement in abdominal pain, constipation, diarrhea, incomplete emptying, and bloating/ abdominal distension. Paroxetine was very well tolerated...
  16. doi request reprint Psychiatric resident and attending diagnostic and prescribing practices
    Adam C Tripp
    SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Acad Psychiatry 32:214-7. 2008
    ..This study investigates whether two patient population groups, under resident or attending treatment, are equivalent or different in the distribution of patient characteristics, diagnoses, or pharmacotherapy...
  17. ncbi request reprint Use of atypical antipsychotics in a Veterans Affairs hospital
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, New York, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:1207-10. 2002
    ....
  18. ncbi request reprint Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression
    Nikhil D Nihalani
    State University of New York, Upstate Medical University, Department of Psychiatry, Syracuse, New York, NY 13210 2375, USA
    Curr Opin Investig Drugs 8:563-9. 2007
    ..In addition, in March 2005 a phase II study of mifepristone as a cognitive enhancer in AD was underway, and in May 2006 a proof-of-concept study in alleviating the weight gain associated with olanzapine had begun...
  19. ncbi request reprint Modafinil treatment for fatigue associated with fibromyalgia
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical Univeristy, Syracuse, New York 13210, USA
    J Clin Rheumatol 13:52. 2007
  20. ncbi request reprint An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy
    Thomas L Schwartz
    Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
    J Clin Psychiatry 65:1223-7. 2004
    ..This study assessed the use of modafinil as an adjunctive treatment in patients with MDD who reported sedation related to serotonergic antidepressant therapy...
  21. pmc Weight gain, obesity, and psychotropic prescribing
    Nikhil Nihalani
    SUNY Upstate Medical University, Syracuse, NY 13210, USA
    J Obes 2011:893629. 2011
    ..The authors undertook a comprehensive literature review in order to present epidemiology, etiology, and treatment options of weight gain associated with antipsychotics, mood stabilizers, and antidepressants...
  22. ncbi request reprint Gamma hydroxy butyric acid and sodium oxybate used to treat posttraumatic stress disorder
    Thomas L Schwartz
    Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, New York, USA
    CNS Spectr 12:884-6. 2007
  23. doi request reprint A neuroscientific update on monoamine oxidase and its inhibitors
    Thomas L Schwartz
    Psychiatry Department, SUNY Upstate Medical University, Syracuse, New York, USA
    CNS Spectr 18:25-32; quiz 33. 2013
    ..These findings and theories will next be translationally discussed in regard to clinical application pertaining to enzyme inhibition and the treatment of major depressive and other psychiatric disorders. ..
  24. ncbi request reprint Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues
    Prakash S Masand
    Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, USA
    Am J Ther 9:484-7. 2002
    ..066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes...
  25. ncbi request reprint Psychotropic drug-induced weight gain alleviated with orlistat: a case series
    Thomas L Schwartz
    Upstate Medical University, State University of New York, Syracuse, New York, USA
    Psychopharmacol Bull 37:5-9. 2003
    ..The results showed that orlistat, administered in 3 daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 35% during an acute treatment period of about 3 months...
  26. ncbi request reprint The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    Psychopharmacol Bull 36:53-7. 2002
    ..Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety...